118 related articles for article (PubMed ID: 34102779)
1. Role of PSA Kinetics in Hormone-refractory Prostate Cancer.
Sabur V; Untan I; Tatlisen A
J Coll Physicians Surg Pak; 2021 Jun; 31(6):673-678. PubMed ID: 34102779
[TBL] [Abstract][Full Text] [Related]
2. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time.
Ng MK; Van As N; Thomas K; Woode-Amissah R; Horwich A; Huddart R; Khoo V; Thompson A; Dearnaley D; Parker C
BJU Int; 2009 Apr; 103(7):872-6. PubMed ID: 18990146
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Parra RG; Briganti A; Gianolli L; Montorsi F; Messa C
Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
6. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
7. Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.
Spurgeon SE; Mongoue-Tchokote S; Collins L; Priest R; Hsieh YC; Peters LM; Beer TM; Mori M; Garzotto M
Urology; 2007 May; 69(5):931-5. PubMed ID: 17482937
[TBL] [Abstract][Full Text] [Related]
8. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
Hanlon AL; Diratzouian H; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
[TBL] [Abstract][Full Text] [Related]
9. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients.
Iremashvili V; Manoharan M; Lokeshwar SD; Rosenberg DL; Pan D; Soloway MS
BJU Int; 2013 Mar; 111(3):396-403. PubMed ID: 22703025
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively.
O'Brien MF; Cronin AM; Fearn PA; Savage CJ; Smith B; Stasi J; Scardino PT; Fisher G; Cuzick J; Møller H; Oliver RT; Berney DM; Foster CS; Eastham JA; Vickers AJ; Lilja H;
Int J Cancer; 2011 May; 128(10):2373-81. PubMed ID: 20658531
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.
Semeniuk RC; Venner PM; North S
Urology; 2006 Sep; 68(3):565-9. PubMed ID: 17010728
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
[TBL] [Abstract][Full Text] [Related]
14. Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer.
Metwalli AR; Rosner IL; Cullen J; Chen Y; Brand T; Brassell SA; Lesperance J; Porter C; Sterbis J; McLeod DG
Urol Oncol; 2014 Aug; 32(6):761-8. PubMed ID: 24929891
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Ross AE; Loeb S; Landis P; Partin AW; Epstein JI; Kettermann A; Feng Z; Carter HB; Walsh PC
J Clin Oncol; 2010 Jun; 28(17):2810-6. PubMed ID: 20439642
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer.
Kim M; Lee J; Jeong CW; Ku JH; Kim HH; Kwak C
Urol Oncol; 2015 May; 33(5):203.e1-9. PubMed ID: 25726498
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting
Yoon J; Ballas L; Desai B; Jadvar H
World J Nucl Med; 2017; 16(3):229-236. PubMed ID: 28670183
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
[TBL] [Abstract][Full Text] [Related]
19. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
Pinsky PF; Andriole G; Crawford ED; Chia D; Kramer BS; Grubb R; Greenlee R; Gohagan JK
Cancer; 2007 Apr; 109(8):1689-95. PubMed ID: 17330856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
